Low Serum IGF-1 in Boys with Recent Onset of Juvenile Idiopathic Arthritis
Table 1
Clinical and demographic characteristics of boys and girls with early JIA (≤1 month from diagnosis) and established disease (>1 month from diagnosis).
Early JIA all ()
Establ JIA all ()
Early JIA boys ()
Early JIA girls ()
Establ JIA boys ()
Establ JIA girls ()
Age at inclusion, years (mean ± SD)
9.7 ± 4.0
10.8 ± 4.6
9.3 ± 3.8
10.0 ± 4.2
10.8 ± 4.6
10.7 ± 4.6
Age at diagnosis, years (mean ± SD)
9.7 ± 4.0
9.4 ± 4.3
9.3 ± 3.8
10.0 ± 4.2
9.3 ± 4.1
9.1 ± 4.6
Disease duration, months (mean ± SD)
0.06 ± 0.2
17.9 ± 14.0
0.0 ± 0
0.1 ± 0.3
19.2 ± 13.7
16.9 ± 14.4
DMARDs, (%)§
9 of 60 (15)
26/35 (74)
4/26 (15)
5/34 (15)
14/16 (87)
12/19 (63)
Steroids, (%)§
5 of 60 (8)
6/35 (17)
2/26 (8)
3/34 (9)
1/16 (6)
5/19 (26)
ANA-positive, (%) §
16 of 50 (32)
6/21 (29)
3/19 (16)
13/31 (42)
5/11 (45)
1/10 (10)
HLAB27-positive, (%) §
18 of 62 (29)
20/63 (32)
10/26 (38)
8/36 (22)
8/28 (29)
11/34 (32)
RF-positive, (%)
2 of 51 (4)
3/29 (10)
0/21 (0)
2/30 (7)
1/15 (7)
2/14 (14)
SJC, (median, IQR)
1 (1–3)
1 (0–2.5)
2 (1–4)
1 (0.25–2.75)
1.5 (0–3.5)
1 (0–2.5)
TJC, (median, IQR)
1 (0–1)
1 (0–1.75)
1 (0–1)
0.5 (0–1)
0 (0–0)
0 (0–2)
ESR at diagnosis, mm/h (median, IQR)
15 (7–29)
11 (6–25)
13 (8–32)
15 (7–28)
15 (7–26)
7 (5–21)
CRP mg/l, median (IQR) #
39 (30–63)
48 (18–115)
42 (26–59)
38 (32–128)
80 (18–130)
33 (22–133)
Neutrophils at diag, % (median, IQR)
53 (46–62)
60 (49–67)
51 (46–66)
54 (44–62)
61 (48–69)
59 (48–66)
JIA categories, (%)
(i) Oligoarthritis, persistent
16 (25)
33 (50)
7 (26)
9 (24)
18 (62)
15 (41)
(ii) Oligoarthritis, extended
11 (17)
8 (12)
3 (11)
8 (21)
2 (7)
6 (16)
(iii) Polyarthritis, RF-positive
2 (3)
3 (5)
0
2 (5)
1 (3)
2 (5)
(iv) Polyarthritis, RF-negative
15 (23)
16 (24)
5 (19)
10 (26)
4 (14)
12 (32)
(v) Enthesitis-related
8 (12)
1 (2)
6 (22)
2 (5)
1 (3)
0
(vi) Systemic
4 (6)
3 (5)
1 (4)
3 (8)
3 (10)
0
(vii) Psoriatic
4 (6)
0 (0)
2 (7)
2 (5)
0
0
(viii) Other
5 (8)
1 (2) †
3 (11)
2 (5)
0
2 (5) †
IQR: interquartile range. §Data for ANA, HLAB27, and treatment not available for all children in the cohort. #Median CRP values shown for children with increased CRP. †Category missing for one patient. Statistical comparisons between all early JIA vs. all established JIA: ,, and .
